Arch Biopartners Total Debt vs. Cash Flow From Operations

ARCH Stock  CAD 1.95  0.01  0.51%   
Based on Arch Biopartners' profitability indicators, Arch Biopartners' profitability may be sliding down. It has an above-average odds of reporting lower numbers next quarter. Profitability indicators assess Arch Biopartners' ability to earn profits and add value for shareholders. Price To Sales Ratio is likely to drop to 1.78 in 2024. Days Sales Outstanding is likely to drop to 17.29 in 2024. At this time, Arch Biopartners' Total Other Income Expense Net is fairly stable compared to the past year. Interest Income is likely to climb to about 20 K in 2024, despite the fact that Income Before Tax is likely to grow to (3.1 M).
For Arch Biopartners profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Arch Biopartners to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Arch Biopartners utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Arch Biopartners's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Arch Biopartners over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Please note, there is a significant difference between Arch Biopartners' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arch Biopartners is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arch Biopartners' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Arch Biopartners Cash Flow From Operations vs. Total Debt Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Arch Biopartners's current stock value. Our valuation model uses many indicators to compare Arch Biopartners value to that of its competitors to determine the firm's financial worth.
Arch Biopartners is rated second in total debt category among its peers. It is number one stock in cash flow from operations category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Arch Biopartners' earnings, one of the primary drivers of an investment's value.

Arch Total Debt vs. Competition

Arch Biopartners is rated second in total debt category among its peers. Total debt of Health Care industry is presently estimated at about 40.95 Million. Arch Biopartners retains roughly 5.02 Million in total debt claiming about 12% of equities under Health Care industry.
Total debt  Valuation  Workforce  Capitalization  Revenue

Arch Cash Flow From Operations vs. Total Debt

Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.

Arch Biopartners

Total Debt

 = 

Bonds

+

Notes

 = 
5.02 M
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.

Arch Biopartners

Operating Cash Flow

 = 

EBITDA

-

Taxes

 = 
(234.07 K)
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.

Arch Cash Flow From Operations Comparison

Arch Biopartners is currently under evaluation in cash flow from operations category among its peers.

Arch Biopartners Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Arch Biopartners, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Arch Biopartners will eventually generate negative long term returns. The profitability progress is the general direction of Arch Biopartners' change in net profit over the period of time. It can combine multiple indicators of Arch Biopartners, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Operating Income-4.7 M-4.5 M
Income Before Tax-3.2 M-3.1 M
Total Other Income Expense Net1.9 MM
Net Loss-3 M-2.8 M
Income Tax Expense-237.7 K-225.8 K
Net Loss-3 M-3.1 M
Net Loss-1.3 M-1.3 M
Net Interest Income-308.2 K-292.8 K
Interest Income19 K20 K
Change To Netincome2.2 M2.3 M
Net Loss(0.18)(0.17)
Income Quality 0.38  0.33 
Net Income Per E B T 1.01  0.96 

Arch Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Arch Biopartners. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Arch Biopartners position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Arch Biopartners' important profitability drivers and their relationship over time.

Use Arch Biopartners in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Arch Biopartners position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Arch Biopartners will appreciate offsetting losses from the drop in the long position's value.

Arch Biopartners Pair Trading

Arch Biopartners Pair Trading Analysis

The ability to find closely correlated positions to Arch Biopartners could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Arch Biopartners when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Arch Biopartners - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Arch Biopartners to buy it.
The correlation of Arch Biopartners is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Arch Biopartners moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Arch Biopartners moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Arch Biopartners can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Arch Biopartners position

In addition to having Arch Biopartners in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Broad Commodities ETFs Thematic Idea Now

Broad Commodities ETFs
Broad Commodities ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Broad Commodities ETFs theme has 26 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Broad Commodities ETFs Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Arch Stock Analysis

When running Arch Biopartners' price analysis, check to measure Arch Biopartners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arch Biopartners is operating at the current time. Most of Arch Biopartners' value examination focuses on studying past and present price action to predict the probability of Arch Biopartners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arch Biopartners' price. Additionally, you may evaluate how the addition of Arch Biopartners to your portfolios can decrease your overall portfolio volatility.